Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis

被引:33
作者
Choi, Hayoung [1 ]
Lee, Hyun [2 ]
Jeon, Kyeongman [3 ]
Suh, Gee Young [3 ]
Shin, Sumin [4 ]
Kim, Hong Kwan [4 ]
Kim, Kyunga [5 ,6 ]
Jeong, Daecheon [5 ]
Kim, Hojoong [3 ]
机构
[1] Hallym Univ, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Kangnam Sacred Heart Hosp, Seoul, South Korea
[2] Hanyang Univ, Dept Internal Med, Div Pulm Med & Allergy, Coll Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac & Cardiovasc Surg, Seoul, South Korea
[5] Samsung Med Ctr, Res Inst Future Med, Stat & Data Ctr, Seoul, South Korea
[6] Sungkyunkwan Univ, SAHIST, Dept Digital Hlth, Seoul, South Korea
关键词
Invasive fungal infection; mucormycosis; survival; thoracic surgery; MYCOSES STUDY-GROUP; EUROPEAN-ORGANIZATION; FUNGAL-INFECTIONS; THERAPY; EPIDEMIOLOGY; ZYGOMYCOSIS; MALIGNANCY; MORTALITY; LEUKEMIA; DISEASES;
D O I
10.21037/jtd.2019.01.75
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Surgical resection is the cornerstone treatment for pulmonary mucormycosis, a lethal fungal infection. It is unclear why some patients do not receive surgery, and the natural courses of these patients have not been well evaluated. Methods: A retrospective review was performed using the medical records of 20 patients with pathologically-confirmed pulmonary mucormycosis. We evaluated the reasons for not receiving surgery and compared treatment outcomes between patients who did and did not undergo surgery. Results: Overall survival rate was 50%. Nine of 11 (82%) patients who underwent surgery survived; however, only 1 of 9 (11%) patients who did not undergo surgery survived. Reasons for not receiving surgery were death shortly after diagnosis (n=1), altered mental state (n=1), refractory underlying disease (n=3), and refusal by patient due to concern of operative risk (n=4). Patients who did not undergo surgery were more likely to be older (P=0.018), have a longer duration of steroid use (P=0.021), higher lactate dehydrogenase level (P=0.039), higher sequential organ failure assessment (SOFA) score (P=0.035), and higher rate of cytomegalovirus (CMV) infection (P=0.020) than those did receive surgery. Surgery was the only favorable survival factor in multivariable analyses (adjusted odds ratio for survival =15.45; P=0.029). Conclusions: The main reasons for not undergoing surgery in patients with pulmonary mucormycosis were the gravity of underlying diseases and concerns for operative risk. Although overall survival rate was poor, it was significantly higher in patients who received pulmonary resection surgery. The decision to undergo lung resection is time-sensitive and essential in improving survival rate in patients suffering from pulmonary mucormycosis, despite perioperative risks.
引用
收藏
页码:892 / +
页数:10
相关论文
共 25 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]   Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997-2006 [J].
Bitar, Dounia ;
Van Cauteren, Dieter ;
Lanternier, Fanny ;
Dannaoui, Eric ;
Che, Didier ;
Dromer, Francoise ;
Desenclos, Jean-Claude ;
Lortholary, Olivier .
EMERGING INFECTIOUS DISEASES, 2009, 15 (09) :1395-1401
[3]   Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with Hematologic malignancy who have zygomycosis [J].
Chamilos, Georgios ;
Lewis, Russell E. ;
Kontoyiannis, Dimitrios P. .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (04) :503-509
[4]   Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].
De Pauw, Ben ;
Walsh, Thomas J. ;
Donnelly, J. Peter ;
Stevens, David A. ;
Edwards, John E. ;
Calandra, Thierry ;
Pappas, Peter G. ;
Maertens, Johan ;
Lortholary, Olivier ;
Kauffman, Carol A. ;
Denning, David W. ;
Patterson, Thomas F. ;
Maschmeyer, Georg ;
Bille, Jacques ;
Dismukes, William E. ;
Herbrecht, Raoul ;
Hope, William W. ;
Kibbler, Christopher C. ;
Kullberg, Bart Jan ;
Marr, Kieren A. ;
Munoz, Patricia ;
Odds, Frank C. ;
Perfect, John R. ;
Restrepo, Angela ;
Ruhnke, Markus ;
Segal, Brahm H. ;
Sobel, Jack D. ;
Sorrell, Tania C. ;
Viscoli, Claudio ;
Wingard, John R. ;
Zaoutis, Theoklis ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821
[5]   BIAS REDUCTION OF MAXIMUM-LIKELIHOOD-ESTIMATES [J].
FIRTH, D .
BIOMETRIKA, 1993, 80 (01) :27-38
[6]   Pulmonary Mucormycosis [J].
Hamilos, Georgios ;
Samonis, George ;
Kontoyiannis, Dimitrios P. .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 32 (06) :693-702
[7]   Fleischner Society:: Glossary of terms tor thoracic imaging [J].
Hansell, David M. ;
Bankier, Alexander A. ;
MacMahon, Heber ;
McLoud, Theresa C. ;
Mueller, Nestor L. ;
Remy, Jacques .
RADIOLOGY, 2008, 246 (03) :697-722
[8]  
Hong Y, 2017, ACUTE CRIT CARE, V32, P205, DOI 10.4266/kjccm.2017.00150
[9]   How I treat mucormycosis [J].
Kontoyiannis, Dimitrios P. ;
Lewis, Russell E. .
BLOOD, 2011, 118 (05) :1216-1224
[10]   Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS:: Comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997 [J].
Kume, H ;
Yamazaki, T ;
Abe, M ;
Tanuma, H ;
Okudaira, M ;
Okayasu, I .
PATHOLOGY INTERNATIONAL, 2003, 53 (11) :744-750